Velaglucerase Alfa
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Velaglucerase alfa: From Gaucher Disease to Steel Syndrome
One-Sentence Summary
Velaglucerase alfa is an enzyme replacement therapy originally used to treat Gaucher disease. The TxGNN model predicts it may be effective for Steel syndrome, but there are currently 0 clinical trials and 0 publications supporting this direction. The prediction is based on the knowledge-graph model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Gaucher disease |
| Predicted New Indication | Steel syndrome |
| TxGNN Prediction Score | 96.99% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, velaglucerase alfa is a recombinant glucocerebrosidase (GBA1) enzyme replacement therapy. It breaks down glucosylceramide that accumulates in Gaucher disease.
Steel syndrome is a skeletal dysplasia caused by COL27A1 variants, which is a collagen disorder. It has no known glucosylceramide accumulation pathway. No established mechanistic link therefore exists between the original and the predicted indication. The high score (0.970) is a graph-based prediction only. It is not supported by any trial or publication, and it should be treated as a hypothesis, not as evidence.
Other predicted indications (all L5, all Hold):
| Rank | Predicted Indication | Score | Assessment |
|---|---|---|---|
| 2 | Esophageal varices with bleeding | 96.20% | Only an indirect link, through rare portal hypertension in Gaucher disease. Enzyme replacement does not target variceal pathology. |
| 3 | Esophageal varices without bleeding | 96.20% | Same as above. The identical score suggests a duplicate node in the knowledge graph. |
| 4 | Hypophosphatasia | 95.04% | No plausible mechanism. The disease is caused by ALPL deficiency, and a specific enzyme therapy (asfotase alfa) already exists. |
| 5 | Wolman disease with hypolipoproteinemia and acanthocytosis | 93.99% | Weak link as a lysosomal storage disorder. The enzyme (LIPA) and substrates differ. |
| 6 | Autosomal ichthyosis syndrome with fatal disease course | 93.74% | Speculative link through skin ceramide metabolism. The drug does not cross the blood-brain barrier. |
| 7 | Cholesteryl ester storage disease | 92.90% | Same class-level similarity as Wolman disease. Sebelipase alfa is the enzyme-specific option. |
| 8 | Varicose disease | 92.70% | No mechanistic link. Likely a graph artifact. |
| 9 | Growth hormone insensitivity syndrome with immune dysregulation 2 | 92.08% | No mechanistic link. The condition involves STAT5B signalling. |
| 10 | Proximal myopathy with extrapyramidal signs | 92.06% | Only a thematic overlap through GBA1 and parkinsonism. The drug does not act on the central nervous system. |
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16107P | VPRIV Powder for Solution for Infusion 400 units/vial | Injection, powder, lyophilized, for solution | Not stated in the data compiled for this report |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The predictions rest only on the TxGNN model score. No clinical trials or publications support any of the ten predicted indications. For Steel syndrome, no biological link exists between GBA1 enzyme replacement and a COL27A1 collagen disorder.
To proceed, the following is needed:
- Mechanism of action data for velaglucerase alfa
- Package insert warnings and contraindications from the HSA, which are needed for any safety screening
- Preclinical or mechanistic evidence supporting a link to Steel syndrome
- Confirmation of the approved indication text for SIN16107P
- Route compatibility assessment, which is still pending
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.